Mohamed Teleb, Miraie Wardi, Maryna Popp, Komola Azimova, Hasan J. Salameh, Sarmad Said
Department of Internal Medicine, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, TX, USA
Med Sci Rev 2015; 2:49-54
Atrial fibrillation (AF), a common arrhythmia affecting many individuals around the globe, increases the risk of heart failure and thromboembolic events. With the increase in incidence and prevalence of AF, there is a large burden on the current health care system. Typical AF presents secondary to underlying heart disease or hypertension but can also be associated with atrial enlargement with increased pressure or with infiltrative or inflammatory processes in the atria. Warfarin has been the anticoagulant of choice for many years, but it requires close monitoring of the International Randomized Ratio (INR). Due to the common adverse effects of warfarin, new oral anticoagulants are under development to aid in decreasing the risk of bleeding without compromising stroke prevention. Edoxaban, a novel factor Xa inhibitor with promising anticoagulation effects with decreased bleeding, has recently been introduced. In this review, we will present the clinical trials that evaluated the efficacy of edoxaban, with emphasis on those which compared edoxaban to warfarin with regards to stroke prevention, major adverse reactions, and bleeding risk.
Keywords: Anticoagulants, Atrial Fibrillation, Factor Xa